PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT03218826 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

NIH

Sponsor class

Conditions

Advanced Breast Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Prostate Carcinoma
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Castration-Resistant Prostate Carcinoma
Metastatic Breast Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Prostate Carcinoma
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Stage III Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Triple-Negative Breast Carcinoma
Unresectable Solid Neoplasm

Interventions

DRUG: Docetaxel
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: PI3Kbeta Inhibitor AZD8186

Sponsor

National Cancer Institute (NCI)